Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hoshimi Okawa"'
Autor:
Hoshimi Okawa, Kenta Kono, Haruo Imawaka, Toru Maruyama, Hiroshi Watanabe, Ken-ichi Nunoya, Yukina Fukuchi
Publikováno v:
Molecular Pharmaceutics. 16:4131-4138
ONO-2160 is a newly developed oral ester-type prodrug of levodopa for removing the problems in use of levodopa. It has a structure in which two of the same substituents are bound to levodopa. It is important to understand the pharmacokinetics and met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81554df3955232975a5e96db3cc0423
https://doi.org/10.1021/acs.molpharmaceut.9b00435
https://doi.org/10.1021/acs.molpharmaceut.9b00435
Autor:
Masaru Mori, Hoshimi Okawa, Yuko Jin, Masaki Matsuura, Nariyasu Mano, Takahiro Maejima, Yasuteru Kondo, Kanehiko Hisamichi, Yuta Kataoka, Tooru Shimosegawa, Miki Shimada, Masamitsu Maekawa, Hiroyuki Suzuki
Publikováno v:
The Tohoku Journal of Experimental Medicine. 237:173-182
Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). However, due to its adverse effects, 20% of patients must discontinue sorafenib within 1 month after first administr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c8de08b07d99fedbad6b8c2173e31ed
https://doi.org/10.1620/tjem.237.173
https://doi.org/10.1620/tjem.237.173
Autor:
Hoshimi Okawa, Masami Tsuchiya, Kanehiko Hisamichi, Takahiro Maejima, Miki Shimada, Nariyasu Mano, Kazutoshi Akasaka, Yasuteru Kondo, Masaki Matsuura, Toshiki Yanagi, Masaru Mori, Tooru Shimosegawa, Masamitsu Maekawa, Hiroyuki Suzuki
Publikováno v:
The Tohoku Journal of Experimental Medicine. 233:103-112
Sorafenib, an oral multi-kinase inhibitor, has been approved for treatment of advanced renal-cell and hepatocellular carcinoma (HCC). However, 20% of HCC patients taking sorafenib are forced to withdraw due to adverse effects within one month after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adb57ff0d7bf0afcc3fd540a2c660698
https://doi.org/10.1620/tjem.233.103
https://doi.org/10.1620/tjem.233.103
Autor:
Miki, Shimada, Hoshimi, Okawa, Yasuteru, Kondo, Takahiro, Maejima, Yuta, Kataoka, Kanehiko, Hisamichi, Masamitsu, Maekawa, Masaki, Matsuura, Yuko, Jin, Masaru, Mori, Hiroyuki, Suzuki, Tooru, Shimosegawa, Nariyasu, Mano
Publikováno v:
The Tohoku journal of experimental medicine. 237(3)
Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). However, due to its adverse effects, 20% of patients must discontinue sorafenib within 1 month after first administr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59ef39a6ec2c4e136d6e53cc30ced4ce
https://pubmed.ncbi.nlm.nih.gov/26477611
https://pubmed.ncbi.nlm.nih.gov/26477611
Autor:
Kenta Kono, Yukina Fukuchi, Hoshimi Okawa, Ken-ichi Nunoya, Haruo Imawaka, Hiroshi Watanabe, Toru Maruyama
Publikováno v:
Molecular Pharmaceutics; 10/7/2019, Vol. 16 Issue 10, p4131-4138, 8p
Autor:
Miki, Shimada, Hoshimi, Okawa, Takahiro, Maejima, Toshiki, Yanagi, Kanehiko, Hisamichi, Masaki, Matsuura, Kazutoshi, Akasaka, Masami, Tsuchiya, Yasuteru, Kondo, Tooru, Shimosegawa, Masaru, Mori, Masamitsu, Maekawa, Hiroyuki, Suzuki, Nariyasu, Mano
Publikováno v:
The Tohoku journal of experimental medicine. 233(2)
Sorafenib, an oral multi-kinase inhibitor, has been approved for treatment of advanced renal-cell and hepatocellular carcinoma (HCC). However, 20% of HCC patients taking sorafenib are forced to withdraw due to adverse effects within one month after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f37b015f04234d61928be6f1077e4173
https://pubmed.ncbi.nlm.nih.gov/24872323
https://pubmed.ncbi.nlm.nih.gov/24872323